Home Industry News

Industry News

News from pharmaceutical companies and other related healthcare organizations

Two clinical trials for acromegaly patients: see if you are eligible.

Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of...

News on Signifor, Signifor LAR, and newly approved Cushing’s drug ISTURISA

Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products...

Big news for acromegaly at Crinetics

From the desk of J D Faccinetti - co-founder - The company recently kicked off a phase 3 trial for their new nonpeptide oral...

Exciting news for acromegaly and NET’s from Crinetics Pharmaceuticals!

In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808)....

Emotional wellness with acromegaly

Kudos to Pfizer's new series on patient support.  The first one features critical advice on emotional and mental help support! The materials provide valuable...

A new drug for Cushing’s: Learn more

In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing's disease recently approved in the US.  

From Endocrine Web: New Oral Acromegaly Treatment Has No Needles Required

From the editors' desk - A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly.  The drug currently...

More news on Isturisa for Cushing’s

In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States,...

More information on Recordati’s new Cushing’s drug Isturisa

In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and...

Crinetics new drug candidate for acromegaly Paltusotine awarded Orphan Drug Designation

From a Crinetics Pharmaceutical press release:  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...

NEWS YOU CAN USE

Articles you may like